Andreas Emmenegger
Director/Board Member at LUZERNER KANTONALBANK AG
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Burns | M | 76 |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 7 years |
| Marcel Hurschler | M | 57 | 31 years | |
| Vito Palombella | M | 61 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 years |
| Sandipkumar S. Kapadia | M | 54 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 years |
| Michael Vasconcelles | M | 61 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 years |
| Paul Alois Zumbühl | M | 67 | 24 years | |
| Steven Holtzman | M | 70 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 10 years |
| Dominik Höchli | M | 57 | 3 years | |
| Peter Felder | M | - | - | |
| Daniel Steiner | M | - | 13 years | |
| Markus Hongler | M | 67 | 6 years | |
| Stefan Lüthy | M | - | - | |
| Esteban Pombo-Villar | M | - |
Targimmune Therapeutics AG
 Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | - |
| Daniel von Arx | M | - | - | |
| Beat Bieri | M | - | - | |
| Daniel Salzmann | M | 60 | 20 years | |
| Patrick Amstutz | M | 49 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | - |
| Seth D. Lewis | M | - | 5 years | |
| Agnete Brunsvik Fredriksen | M | 47 | 3 years | |
| Gwen A. Fyfe | M | 72 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 5 years |
| Peter Morgan Kash | M | 62 |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | 8 years |
| Simon Kauth | M | 56 | 1 years | |
| Silvana Leasi | F | 43 | 1 years | |
| Michael Pitzner | M | - | 2 years | |
| Alexander Zürcher | M | - | 2 years | |
| Philipp Keist | M | - | - | |
| Nicole Willimann Vyskocil | F | 56 | 3 years | |
| Philippe Legenne | M | - | 4 years | |
| Renate Gloggner | F | - | 3 years | |
| Peter Braun | M | - |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | - |
| Kuno Sommer | M | 68 |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | 7 years |
| Michael Girsberger | M | - | 8 years | |
| Baris Arican | M | - | 2 years | |
| Daniel Bommer | M | - | 9 years | |
| Stefan Angele | M | 56 | 6 years | |
| Alex Fässler | M | 69 |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | - |
| Beat Hodel | M | 58 | 15 years | |
| Stefan Studer | M | 50 | 9 years | |
| Michael Tobias Stumpp | M | 52 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | - |
| Paolo Fundarò | M | 50 |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | 4 years |
| Alexander Levitzki | M | - |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | - |
| Martha Scheiber | M | 59 | 10 years | |
| Roger Studer | M | 57 | 3 years | |
| Konrad Fausch | M | - | 15 years | |
| Christoph Rentsch | M | 65 |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | - |
| Andreas Dietrich | M | 48 | 9 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Zahnd | M | 49 | 12 years | |
| Vladimir Cmiljanovic | M | - |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | - |
| Melanie Rolli | M | 51 |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | - |
| Bernd Giese | M | - |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | - |
| Doris Russi Schurter | F | 68 | 11 years | |
| Markus Bachmann | M | 61 | 12 years | |
| Göran Albert Ando | M | 75 | 10 years | |
| Franz Grüter | M | 61 | 5 years | |
| Andreas Wallnöfer | M | 63 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | 2 years |
| Andreas Harstrick | M | 63 | 4 years | |
| Nicolas Leupin | M | 50 | 4 years | |
| Andreas Voss | M | 65 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | 4 years |
| Antoinette Stocker | F | - | 30 years | |
| Lisa Rojkjaer | M | 58 | - | |
| Dorothée Anna Deuring | F | 55 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | 4 years |
| Jürg Stadelmann | M | - | - | |
| William Lee | M | 69 | 13 years | |
| Christoph Lengwiler | M | 65 | 15 years | |
| Leo Grüter | M | 62 | 12 years | |
| Jeffrey H. Buchalter | M | 67 | 2 years | |
| Horst Wildemann | M | 82 | 19 years | |
| Josef Anton Felder | M | 63 | 14 years | |
| Ralf Rosenow | M | - |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | - |
| Mads Joergensen | M | 55 | 1 years | |
| Hervé Girsault | M | 64 |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | - |
| Pamela A. Trail | M | 68 | 1 years | |
| Stefan Portmann | M | 57 | 7 years | |
| Petri T. Vainio | M | 65 | 11 years | |
| Marco Attilio Ghisalberti | M | 63 | 16 years | |
| Jörn Aldag | M | 65 | 11 years | |
| Julien Gander | M | 45 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 75 | 97.40% |
| United States | 8 | 10.39% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andreas Emmenegger
- Personal Network